Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

CAR-T Digest - August 2020

Weekly Digest - June 2024

18 June 2024: Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One Biopharmaceuticals has secured exclusive global rights, excluding Greater China, for MTX-13, an ADC targeting PTK7, through a license deal with MabCare Therapeutics
The US FDA approved MTX-13’s IND application in April 2024, renaming it DAY301, following promising pre-clinical results demonstrating anticancer efficacy across various solid cancers
MabCare will receive $55 million upfront and could earn up to $1.152 billion in milestones based on research, regulatory, and commercial success, plus low-to-mid single-digit royalties on net sales outside Greater China, as per the license agreement
Phase I trials for DAY301 are expected to commence in late 2024 or early 2025, with the first patient dosed during this period